Introduction: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. Methods: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A "good response" was defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon monoxide (DLCO) >15% and PaO2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan pattern unchanged or improved. Results: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%) patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients showed an improved or stabilized lung disease. Conclusions: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to design future randomized clinical trials for SSc therapeutics.Trial registration: ClinicalTrials.gov NCT00573326. Registered 13 December 2007.

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide : a phase II pilot study / P. Fraticelli, B. Gabrielli, G. Pomponio, G. Valentini, S. Bosello, P. Riboldi, M. Gerosa, P. Faggioli, R. Giacomelli, N. Del Papa, R. Gerli, C. Lunardi, S. Bombardieri, W. Malorni, A. Corvetta, G. Moroncini, A. Gabrielli. - In: ARTHRITIS RESEARCH & THERAPY. - ISSN 1478-6354. - 16:4(2014), pp. R144.1-R144.10. [10.1186/ar4606]

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide : a phase II pilot study

P. Riboldi;M. Gerosa;
2014

Abstract

Introduction: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. Methods: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A "good response" was defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon monoxide (DLCO) >15% and PaO2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan pattern unchanged or improved. Results: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%) patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients showed an improved or stabilized lung disease. Conclusions: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to design future randomized clinical trials for SSc therapeutics.Trial registration: ClinicalTrials.gov NCT00573326. Registered 13 December 2007.
Administration, Oral; Adult; Benzamides; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Function Tests; Scleroderma, Systemic; Tomography, X-Ray Computed; Treatment Outcome; Immunology and Allergy; Immunology; Rheumatology; Medicine (all)
Settore MED/16 - Reumatologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Fraticelli et al ART 2014.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 303.07 kB
Formato Adobe PDF
303.07 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/344713
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 74
social impact